What ECG changes indicate hyperkalemia and what immediate management is recommended?

Hyperkalemia on ECG: Recognition and Immediate Management

The first ECG indicator of hyperkalemia is peaked (tented) T waves, and as potassium rises progressively, you will see flattened/absent P waves, prolonged PR interval, widened QRS complex, deepened S waves, and merging of S and T waves—ultimately progressing to sine-wave pattern, idioventricular rhythms, and asystolic cardiac arrest if untreated 1.

ECG Changes by Severity

The ECG manifestations correlate with serum potassium levels, though individual variation exists 2:

• Early changes (K+ 5.5-6.5 mmol/L): Peaked (tented) T waves—often the first and only warning sign 1
• Moderate changes (K+ 6.5-7.5 mmol/L): Flattened or absent P waves, prolonged PR interval 1, 2
• Severe changes (K+ 7.0-8.0 mmol/L): Widened QRS complex, deepened S waves 1, 2
• Critical changes (K+ >8.0 mmol/L): Merging of S and T waves, sine-wave pattern 1
• Terminal events (K+ >10 mmol/L): Idioventricular rhythms, ventricular fibrillation, asystole, or pulseless electrical activity 1, 2

Critical Caveat

ECG changes do not always correlate predictably with potassium levels—some patients with chronic kidney disease, diabetes, or heart failure may have K+ levels up to 6 mEq/L without ECG changes, while others develop life-threatening arrhythmias at lower thresholds 2, 3. The ECG remains your most important bedside tool for risk stratification 4.

Immediate Management Algorithm

Treatment priority follows three sequential goals: stabilize the myocardial membrane, shift potassium intracellularly, and remove potassium from the body 1, 5, 1.

Step 1: Membrane Stabilization (Acts in 1-3 minutes)

Administer IV calcium immediately if:

• Any ECG changes are present, OR
• Serum K+ ≥6.5 mmol/L 1, 5, 1

Dosing options:

• Calcium chloride 10%: 5-10 mL (500-1000 mg) IV over 2-5 minutes, OR
• Calcium gluconate 10%: 15-30 mL IV over 2-5 minutes 1, 5, 1

This does not lower potassium but protects the heart from arrhythmias by antagonizing potassium's effect on excitable membranes 1.

Step 2: Shift Potassium Intracellularly (Acts in 30-60 minutes)

Administer all three agents simultaneously for maximum effect:

1. Insulin + Glucose (most effective):

   • Mix 10 units regular insulin with 25g glucose (50 mL D50) IV over 15-30 minutes 1, 5, 1
   • Warning: Monitor for hypoglycemia, especially in non-diabetic patients with low baseline glucose 6

2. Nebulized albuterol (synergistic with insulin):

   • 10-20 mg nebulized over 15 minutes 1, 5, 1
   • Provides effective potassium-lowering and works synergistically with insulin 6

3. Sodium bicarbonate (only if metabolic acidosis present):

   • 50 mEq IV over 5 minutes 1
   • Limited indication—use only in patients with severe metabolic acidosis 5, 6

These therapies are temporary and may need to be repeated—they shift potassium but do not remove it from the body 1.

Step 3: Remove Potassium from the Body

Choose based on clinical context:

• Loop diuretics: Furosemide 40-80 mg IV if patient has hypervolemia and is non-oliguric 1, 5
• Hemodialysis: Definitive treatment for patients with oliguria, end-stage renal disease, or refractory hyperkalemia 1, 5
• Potassium binders (newer agents preferred):
  • Sodium zirconium cyclosilicate or patiromer for ongoing management 5
  • Avoid sodium polystyrene sulfonate (Kayexalate)—questionable efficacy and risk of severe gastrointestinal adverse events 6

Cardiac Arrest Management

If cardiac arrest occurs secondary to hyperkalemia, administer all the above adjuvant therapies in addition to standard ACLS (Class IIb recommendation) 1. The combination of calcium, insulin/glucose, and albuterol should be given during resuscitation efforts.

Post-Acute Management Considerations

After stabilization, identify and address reversible precipitating factors 7:

• Review medications (RAASi, potassium-sparing diuretics, NSAIDs, trimethoprim-sulfamethoxazole) 3
• Assess renal function
• Evaluate for tissue breakdown, hemolysis, or adrenal insufficiency

Do not discontinue RAASi therapy reflexively—these medications reduce mortality in heart failure and chronic kidney disease. Instead, treat hyperkalemia with potassium binders to allow continuation of life-saving RAASi therapy 5, 3, 7.

Monitoring Strategy

Serial ECGs and potassium measurements are essential—hyperkalemia frequently recurs, and treatment effects are temporary 4, 8. Reassess potassium within 1 hour after initial treatment, then frequently until stable 5, 7.